The FDA-approved combination of pembrolizumab with trastuzumab and platinum-fluoropyrimidine chemo in HER2+ gastric or GEJ cancers adds immunotherapy to targeted regimens, significantly improving outcomes. https://www.einpresswire.com/article/833965726/her2-gastric-cancer-therapy-market-set-for-steady-growth-by-2033-datam-intelligence